This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Masi, G. Articles by De Vito, G. Search for Related Content PubMed PubMed Citation Articles by Masi, G. Articles by De Vito, G. Social Bookmarking                   What's this?

Risperidone Monotherapy in Preschool Children With Pervasive Developmental Disorders

Division of Child Neurology and Psychiatry, University of Pisa, and the Instituto di Ricovero e Cura a Carattere Scientifico Stella Maris, Calambrone, Pisa, Italy, masi@.inpe.unipi.it

Angela Cosenza, MD

Division of Child Neurology and Psychiatry, University of Pisa, and the Instituto di Ricovero e Cura a Carattere Scientifico Stella Maris, Calambrone, Pisa, Italy

Maria Mucci, MD

Division of Child Neurology and Psychiatry, University of Pisa, and the Instituto di Ricovero e Cura a Carattere Scientifico Stella Maris, Calambrone, Pisa, Italy

Giuseppe De Vito, MD

Division of Child Neurology and Psychiatry, University of Pisa, and the Instituto di Ricovero e Cura a Carattere Scientifico Stella Maris, Calambrone, Pisa, Italy

The aim of this preliminary study was to examine the short-term efficacy and safety of the atypical antipsychotic risperidone in preschool autistic children. The sample consisted of 10 subjects (7 males and 3 females) aged 39/12 to 66/12 years (mean age 4.7 years). A 16-week open-label trial with risperidone monotherapy was initiated at a starting dose of 0.25 mg daily and was increased to a maximum dose of 0.50 mg (0.027 mg/kg daily). Outcome measures were the Childhood Autism Rating Scale, the Children's Psychiatric Rating Scale, Clinical Global Impression (improvement score), and the Children's Global Assessment of Functioning. Two subjects did not complete the trial because of side effects (tachycardia and flushes, fever and hyporexia). After the 16-week treatment, data from the eight children who completed the trial indicated a modest improvement in the Childhood Autism Rating Scale total score, Children's Psychiatric Rating Scale total score, and Children's Global Assessment of Functioning. According to the Clinical Global Impression, the global improvement score for four subjects was much improved or very much improved; the score for the other four children was minimally improved. None of the children exhibited behavioral deterioration. The side effects in the eight children were not severe. (J Child Neurol 2001;16:395-400).

Journal of Child Neurology, Vol. 16, No. 6, 395-400 (2001)
DOI: 10.1177/088307380101600602


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Feroz-Nainar and M. Roy Risperidone and late onset tics Autism, May 1, 2006; 10(3): 302 - 307. [PDF]

				O. Dinca, M. Paul, and N. J. Spencer Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders J Psychopharmacol, September 1, 2005; 19(5): 521 - 532. [Abstract] [PDF]

				S. Shea, A. Turgay, A. Carroll, M. Schulz, H. Orlik, I. Smith, and F. Dunbar Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders Pediatrics, November 1, 2004; 114(5): e634 - e641. [Abstract] [Full Text] [PDF]